The Rational Selection for Solubilized Formulation Technologies Utilizing Physicochemical Properties.

IF 1.3 4区 医学 Q4 CHEMISTRY, MEDICINAL
Kouya Kimoto, Katsuhiko Yamamoto, Toshiro Fukami, Yukihiro Ikeda
{"title":"The Rational Selection for Solubilized Formulation Technologies Utilizing Physicochemical Properties.","authors":"Kouya Kimoto, Katsuhiko Yamamoto, Toshiro Fukami, Yukihiro Ikeda","doi":"10.1248/cpb.c25-00434","DOIUrl":null,"url":null,"abstract":"<p><p>Enhancing the solubility of poorly water-soluble oral small-molecule drugs remains a critical challenge in the pharmaceutical industry, particularly during the early stages of drug development when selecting solubilized formulation technologies. This difficulty largely stems from the absence of objective indicators for comparing formulations. This study aimed to establish the selection indicators for solubilized formulation technologies based on applicable formulation preparation among amorphous solid dispersion (ASD), cyclodextrin (CD), lipid-based formulation (LBF), and nanocrystal (NC), utilizing the overall molecular properties, such as molecular weight, melting point (T<sub>m</sub>), Log P, and polar surface area (PSA) in the marketed oral drugs employing solubilized formulation technologies. Single-property plots of the selected properties revealed the regions of higher or lower frequency in the selected molecular properties. The multiple property plot with T<sub>m</sub> and the combined property of normalized Log P and PSA identified a specific area as the optimal range for selecting ASD, LBF, and NC, while excluding CD. These findings are expected to function as guide indicators that enable the rational selection of formulation technologies and serve as a foundational approach to accelerating development timelines based on molecular properties available during the early stages of drug development.</p>","PeriodicalId":9773,"journal":{"name":"Chemical & pharmaceutical bulletin","volume":"73 9","pages":"857-867"},"PeriodicalIF":1.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemical & pharmaceutical bulletin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1248/cpb.c25-00434","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Enhancing the solubility of poorly water-soluble oral small-molecule drugs remains a critical challenge in the pharmaceutical industry, particularly during the early stages of drug development when selecting solubilized formulation technologies. This difficulty largely stems from the absence of objective indicators for comparing formulations. This study aimed to establish the selection indicators for solubilized formulation technologies based on applicable formulation preparation among amorphous solid dispersion (ASD), cyclodextrin (CD), lipid-based formulation (LBF), and nanocrystal (NC), utilizing the overall molecular properties, such as molecular weight, melting point (Tm), Log P, and polar surface area (PSA) in the marketed oral drugs employing solubilized formulation technologies. Single-property plots of the selected properties revealed the regions of higher or lower frequency in the selected molecular properties. The multiple property plot with Tm and the combined property of normalized Log P and PSA identified a specific area as the optimal range for selecting ASD, LBF, and NC, while excluding CD. These findings are expected to function as guide indicators that enable the rational selection of formulation technologies and serve as a foundational approach to accelerating development timelines based on molecular properties available during the early stages of drug development.

利用理化性质合理选择增溶制剂工艺。
提高水溶性差的口服小分子药物的溶解度仍然是制药业面临的一个关键挑战,特别是在药物开发的早期阶段选择增溶制剂技术时。这一困难主要是由于缺乏比较各种方法的客观指标。本研究旨在利用已上市的采用增溶剂型技术的口服药物的总体分子性质,如分子量、熔点(Tm)、logp和极性表面积(PSA)等,在非晶固体分散体(ASD)、环糊精(CD)、脂质基制剂(LBF)和纳米晶制剂(NC)中,建立基于适用剂型制备的增溶剂型技术选择指标。所选性质的单性质图显示了所选分子性质中频率较高或较低的区域。利用Tm和归一化Log P和PSA的组合特性绘制的多重特性图确定了一个特定区域作为选择ASD、LBF和NC的最佳范围,同时排除了CD。这些发现有望作为指导指标,使配方技术能够合理选择,并作为基于药物开发早期可用的分子特性加快开发时间表的基础方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.20
自引率
5.90%
发文量
132
审稿时长
1.7 months
期刊介绍: The CPB covers various chemical topics in the pharmaceutical and health sciences fields dealing with biologically active compounds, natural products, and medicines, while BPB deals with a wide range of biological topics in the pharmaceutical and health sciences fields including scientific research from basic to clinical studies. For details of their respective scopes, please refer to the submission topic categories below. Topics: Organic chemistry In silico science Inorganic chemistry Pharmacognosy Health statistics Forensic science Biochemistry Pharmacology Pharmaceutical care and science Medicinal chemistry Analytical chemistry Physical pharmacy Natural product chemistry Toxicology Environmental science Molecular and cellular biology Biopharmacy and pharmacokinetics Pharmaceutical education Chemical biology Physical chemistry Pharmaceutical engineering Epidemiology Hygiene Regulatory science Immunology and microbiology Clinical pharmacy Miscellaneous.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信